Ampligen Cost Recovery Program
For research, treatments, and personal stories regarding Chronic Fatigue Syndrome/ME/SEID. Explore the. Marvel at our, or read our exciting and informative.
An open thread discussing the best options. View our Public Moderation Logs. Related subreddits. (Ehlers-Danlos Syndrome). (Fitness for the chronically ill). Medical Information Disclaimer The Website is not a forum for the exchange of medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide).
PHILADELPHIA, March 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the 'Company' or 'Hemispherx'), reported today that it has executed an agreement with Emerge Health Pty Ltd. ('Emerge') to seek approval of Ampligen, an experimental immunotherapeutic, for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.
While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted adult that you know or a medical professional. THE INFORMATION ON THIS WEBSITE IS PROVIDED FOR EDUCATIONAL AND ENTERTAINMENT PURPOSES ONLY, AND IS IN NO WAY INTENDED TO DIAGNOSE, CURE, OR TREAT ANY MEDICAL OR OTHER CONDITION.
Define Cost Recovery
ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROVIDER PRIOR TO STARTING ANY NEW DIET AND ASK YOUR DOCTOR ANY QUESTIONS YOU MAY HAVE REGARDING A MEDICAL CONDITION. IN ADDITION TO ALL OTHER LIMITATIONS AND DISCLAIMERS IN THIS AGREEMENT, SERVICE PROVIDER AND ITS THIRD PARTY PROVIDERS DISCLAIM ANY LIABILITY OR LOSS IN CONNECTION WITH THE CONTENT PROVIDED ON THIS WEBSITE. For the last week I've been trying to find a US doctor still using Ampligen.
Ampligen Cost
After numerous calls with the offices of Dr Peterson, Bateman, and Lapp, I discovered that as of 1/30/2017 Hemispherx has discontinued their 511AMP Cost Recovery Program. That means you can't get Ampligen in the US anymore, even if you pay the full price. Hemispherx may roll out a new US trial at the end of the year, but it will be double blind with a placebo, meaning you won't know if you're actually getting treatment. This leaves Europe and Argentina as possible locations to get Ampligen. Even though it's now approved in Argentina, my understanding is that the doctors there do not acknowledge ME, so Europe seems to be the best bet. I contacted a Netherlands based company called myTomorrows that will help set up patients with doctors in Europe who are willing to use Ampligen.
Va Medical Care Cost Recovery Program
They are researching the best option and will contact me next week Update: Found out that Hemispherx is having supply issues with Ampligen and it is not available in Europe or Argentina. So in other words there is no place Earth (to my knowledge) currently offering it.
In this episode of CEOLIVE we’re joined by Mr. Thomas Equels, CEO of Hemispherx Biopharma, which trades on the NYSE under ticker HEB. Hemispherx is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. The new management team has achieved several recent milestones including: 1.
The first shipment of Ampligen delivered for sale in Europe utilizing the Early Access Program (EAP) 2. EAP in Europe extended to pancreatic cancer patients beginning in the Netherlands 3. FDA approval to increase price for US-based Ampligen cost recovery program 4. Initiated a commercial scale production plan with our primary contract manufacturer to meet anticipated future demands in both international programs as well as domestic programs 5. Collaboration with Millions Missing Canada to bring medication to Canadians for ME/CFS 6. Completed an intranasal human safety study of Ampligen plus FluMist® and has commenced full data analysis 7. Top-line results show intranasal Ampligen was generally well-tolerated 8.
Continuing discussions with FDA to identify path toward approval for ME/CFS 9. Cut Burn rate by over 50% and still reached milestones Forward-Looking Statements This CEOLIVE.TV video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.
Contact CEOLIVE.TV Mike Elliott me@ceolive.tv Disclaimer Neither CEOLIVE.TV or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, ceolive.tv/disclaimer. CEOLIVE content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOLIVE content and productions, or other investor relations materials and presentations are subject to change. Neither CEOLIVE nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information are provided for informational or entertainment purposes only.
CEOLIVE is not a registered broker-dealer or a registered investment advisor.